Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
Male
Humans
Prostatic Neoplasms
/ diagnostic imaging
Treatment Outcome
Prostate-Specific Antigen
Androgen Antagonists
/ therapeutic use
Retrospective Studies
Radiosurgery
Neoplasm Recurrence, Local
/ diagnostic imaging
Positron-Emission Tomography
Positron Emission Tomography Computed Tomography
/ methods
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
08
01
2023
accepted:
19
06
2023
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little long-term data is currently available regarding the effectiveness of this approach. A retrospective single institution study of PSMA-PET directed SBRT without initial ADT for oligo-metachronous PCa. Median dose/fractionation was 24 Gy in 2# to bones and 30 Gy in 3# to lymph nodes. The primary endpoint was time to BF (PSA + 0.2 ug/L above nadir). Secondary endpoints included time to ADT for relapse (i.e. palliative ADT), BF defined as PSA nadir + 2 ug/L, toxicity, patterns of failure and survival. Patients were excluded if they received ADT with their SBRT, had short disease-free interval, or > 3 metastases on PSMA-PET. 103 patients treated from November-2014 to December-2019 were analysed from our prospective database. Median follow-up was 5 years. 64 patients were treated for nodal only disease, 35 bone only and 4 mixed. 15% were free of any BF at 5 years with median time to BF of 1.1 years. 32% (33/103) of patients had further curative-intent radiation treatment following their first BF after SBRT, including subsequent SBRT. Eight patients underwent potentially curative treatment for their second or third relapse. Allowing for salvage treatment, 29/103 (28%) were biochemically disease free at last follow up. At 5 years, 39% of patients had never received any ADT and 55% had not started ADT for relapse with a median time to ADT for relapse of 5.5 years. There were 2 grade 3 toxicities (rib fracture and lymphoedema), and no local failures. PSMA-PET guided SBRT for oligo-metachronous PCa recurrence in appropriately triaged patients results in excellent local control, low toxicity and over 50% ADT free at 5 years.
Sections du résumé
BACKGROUND
BACKGROUND
Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little long-term data is currently available regarding the effectiveness of this approach.
METHODS
METHODS
A retrospective single institution study of PSMA-PET directed SBRT without initial ADT for oligo-metachronous PCa. Median dose/fractionation was 24 Gy in 2# to bones and 30 Gy in 3# to lymph nodes. The primary endpoint was time to BF (PSA + 0.2 ug/L above nadir). Secondary endpoints included time to ADT for relapse (i.e. palliative ADT), BF defined as PSA nadir + 2 ug/L, toxicity, patterns of failure and survival. Patients were excluded if they received ADT with their SBRT, had short disease-free interval, or > 3 metastases on PSMA-PET.
RESULTS
RESULTS
103 patients treated from November-2014 to December-2019 were analysed from our prospective database. Median follow-up was 5 years. 64 patients were treated for nodal only disease, 35 bone only and 4 mixed. 15% were free of any BF at 5 years with median time to BF of 1.1 years. 32% (33/103) of patients had further curative-intent radiation treatment following their first BF after SBRT, including subsequent SBRT. Eight patients underwent potentially curative treatment for their second or third relapse. Allowing for salvage treatment, 29/103 (28%) were biochemically disease free at last follow up. At 5 years, 39% of patients had never received any ADT and 55% had not started ADT for relapse with a median time to ADT for relapse of 5.5 years. There were 2 grade 3 toxicities (rib fracture and lymphoedema), and no local failures.
CONCLUSION
CONCLUSIONS
PSMA-PET guided SBRT for oligo-metachronous PCa recurrence in appropriately triaged patients results in excellent local control, low toxicity and over 50% ADT free at 5 years.
Identifiants
pubmed: 37528487
doi: 10.1186/s13014-023-02302-8
pii: 10.1186/s13014-023-02302-8
pmc: PMC10394924
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Androgen Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2022 Apr 21;14(9):
pubmed: 35565207
Front Oncol. 2022 Jun 07;12:898774
pubmed: 35747822
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
Eur Urol Oncol. 2018 Dec;1(6):531-537
pubmed: 31158100
BJU Int. 2016 May;117(5):732-9
pubmed: 26683282
BMC Cancer. 2014 Sep 15;14:671
pubmed: 25223986
Front Oncol. 2015 May 05;5:101
pubmed: 26000249
J Clin Oncol. 2021 Jan 10;39(2):136-144
pubmed: 33275486
Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3289-3294
pubmed: 35298693
Br J Radiol. 2020 Dec 01;93(1116):20200496
pubmed: 32822547
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702
pubmed: 27131082